Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guben Qushi Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is currently being investigated for the treatment of allergic asthma. The formulation is designed based on the TCM principles of "Guben" (strengthening the root or foundation) and "Qushi" (eliminating dampness), which are intended to address the underlying constitutional deficiencies and pathological factors associated with chronic respiratory conditions. Clinical research, including a randomized, double-blind, placebo-controlled pilot study (ChiCTR2200064324), is focused on evaluating its clinical efficacy, safety, and the specific therapeutic mechanisms by which it modulates the allergic response in asthma patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guben Qushi Granule.